Clinical Trial Update: Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the combination of Fruquintinib, Sintilimab, and TACE for inoperable primary hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)
• TACE

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN